Primary neurolymphomatosis is the direct infiltration of lymphomatous neoplastic cells into nerve roots and/or peripheral nerves. A 67-year-old man had a 24-month history of progressive and severe left lower limb neuropathic pain, ipsilateral ankle dorsiflexion weakness and gait disturbance. Gadolinium-enhanced MRI showed thickening and enhancement of the cauda equina, L5, S1 and S2 nerve roots. Fluorodeoxyglucose positron emission tomography showed concordant hypermetabolism. L5 nerve root biopsy confirmed diffuse large B-cell lymphoma. One cycle of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy resulted in remission, but this was not sustained. Primary neurolymphomatosis is rare and diagnostically challenging, and often the diagnosis is delayed. While biopsy is the gold standard for diagnosis, neuroimaging helps to characterise lesions and to determine the feasibility of biopsy.

Download full-text PDF

Source
http://dx.doi.org/10.1136/pn-2023-003977DOI Listing

Publication Analysis

Top Keywords

primary neurolymphomatosis
12
nerve root
8
root biopsy
8
nerve roots
8
neurolymphomatosis diagnosed
4
diagnosed spinal
4
nerve
4
spinal nerve
4
biopsy
4
biopsy primary
4

Similar Publications

Background: Neurolymphomatosis is a lymphoid malignancy of the peripheral nervous system and its natural history is poorly understood.

Methods: We performed PubMed search and extracted clinical data for Kaplan-Meier statistics to determine outcome parameters over time. Kruskal-Wallis test was performed to compare prognostic factors.

View Article and Find Full Text PDF
Article Synopsis
  • Neurolymphomatosis (NL) is a rare condition where lymphoma cells invade the peripheral nervous system, and its treatment options and prognosis are not well-defined.
  • This study investigates predictive factors for secondary NL, revealing common chromosomal abnormalities, like deletions on chromosome 10, which may aid in early detection.
  • When patients with diffuse large B-cell lymphoma show neurological symptoms and chromosomal abnormalities, there’s a potential risk for developing secondary NL that should be evaluated.
View Article and Find Full Text PDF

Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis.

Am J Hematol

December 2024

Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.

Lymphomatous infiltration of the peripheral nervous system (PNS), termed neurolymphomatosis, represents a distinct extranodal non-Hodgkin lymphoma variant with dismal outcome. CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy has emerged as a safe and effective treatment for B-cell lymphomas. We aimed to assess toxicity and efficacy of CD19-CAR T-cells in neurolymphomatosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!